SCHEMBL6093462

SCHEMBL6093462

O=C(Nc1ccc(O)cc1C(=O)O)c1ccccc1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GFER P55789 1/20 0.69
▸ LMNA P02545 6/20 0.62
▸ HTT P42858 4/20 0.62
▸ TP53 P04637 2/20 0.62
▸ NPC1 O15118 2/20 0.62
▸ GAA P10253 1/20 0.62
▸ MEN1 O00255 7/20 0.57
▸ KMT2A Q03164 7/20 0.57
▸ MAPT P10636 5/20 0.57
▸ ALDH1A1 P00352 4/20 0.57
▸ TDP1 Q9NUW8 3/20 0.57
▸ HSD17B10 Q99714 3/20 0.57
▸ KDM4E B2RXH2 3/20 0.57
▸ HPGD P15428 3/20 0.57
▸ TSHR P16473 2/20 0.57
▸ ABL1 P00519 1/20 0.57
▸ RIN1 Q13671 1/20 0.57
▸ RAB9A P51151 3/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ MAPK1 P28482 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6093021 0.89 LMNA (0.60) GFERLMNAHTTTP53NPC1
SCHEMBL28018001 0.88 CA12 (0.66) GFERLMNAHTTMEN1KMT2A
SCHEMBL11788972 0.88 LMNA (0.64) GFERLMNAHTTTP53NPC1
SCHEMBL9973846 0.87 ALDH1A1 (0.63) GFERLMNAHTTMEN1KMT2A
SCHEMBL4669122 0.86 LMNA (0.76) LMNAHTTTP53NPC1GAA
SCHEMBL11405554 0.86 LMNA (0.76) LMNAHTTTP53NPC1GAA
SCHEMBL23796871 0.85 KMT2A (0.62) GFERLMNAHTTMEN1KMT2A
SCHEMBL30032854 0.85 KMT2A (0.62) GFERLMNAHTTMEN1KMT2A
SCHEMBL3685205 0.84 MEN1 (0.59) GFERLMNAHTTTP53NPC1
SCHEMBL30032129 0.83 KMT2A (0.60) GFERLMNAHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY SYMRISE AG (DE) 2023-04-27 — — US disclosed
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY SYMRISE AG (DE) 2023-04-27 — — US disclosed
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE SYMRISE AG (DE) 2023-04-27 — — US disclosed
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE SYMRISE AG (DE) 2023-04-27 — — US disclosed
US-20230118467-A1 COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L SYMRISE AG (DE) 2023-04-20 — — US disclosed
US-8911795-B2 Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching SYMRISE AG (DE) 2014-12-16 — — US disclosed
US-8911795-B2 Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching SYMRISE AG (DE) 2014-12-16 — — US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 — — US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 — — US disclosed
US-8409552-B2 Anthranillic acid amides and derivatives thereof as cosmetic and pharmaceutical active compounds SYMRISE AG (DE) 2013-04-02 — — US disclosed
US-8203016-B2 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents SYMRISE AG (DE) 2012-06-19 — — US disclosed
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching SYMRISE GMBH & CO. KG (DE) 2009-12-03 — — US disclosed
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching SYMRISE GMBH & CO. KG (DE) 2009-12-03 — — US disclosed
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2009-09-10 — — US disclosed
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2009-09-10 — — US disclosed
EP-1886662-A1 Anti-microbial compounds for treating bad breath Symrise GmbH & Co. KG (DE) 2008-02-13 — — EP disclosed
US-20080008660-A1 Antimicrobially active compounds for treating bad breath SYMRISE GMBH & CO. KG (DE) 2008-01-10 — — US disclosed
US-20080008660-A1 Antimicrobially active compounds for treating bad breath SYMRISE GMBH & CO. KG (DE) 2008-01-10 — — US disclosed
WO-2007062957-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING SYMRISE GMBH & CO. KG (DE) 2007-06-07 — — WO disclosed
US-20060089413-A1 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents SYMRISE GMBH & CO. KG (DE) 2006-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089413-A1 Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents HRH1, CMA1, HRH2 GFER 1237/4885LMNA 3937/4885HTT 2533/4885
US-20090297468-A1 Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching H1-0, ASIC1, MCOLN1 GFER 2489/4885LMNA 3814/4885HTT 1970/4885
US-20230129036-A1 AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE HPD, CYP4A22, PAH GFER 2563/4885LMNA 3336/4885HTT 23/4885
US-20090226537-A1 MIXTURES COMPRISING ANTHRANILIC ACID AMIDES AND ANTIDANDRUFF AGENTS AS COSMETIC AND PHARMACEUTICAL COMPOSITIONS FOR ALLEVIATING ITCHING H1-0, ASIC1, NHERF1 GFER 1077/4885LMNA 4326/4885HTT 2035/4885
US-20230131993-A1 COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY OAT, PIGS, HLA-A GFER 3100/4885LMNA 1966/4885HTT 56/4885
US-20080008660-A1 Antimicrobially active compounds for treating bad breath CAT, LPO, GPX1 GFER 943/4885LMNA 4240/4885HTT 3746/4885
US-20230118467-A1 COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L TACR1, NPSR1, TACR2 GFER 1075/4885LMNA 2206/4885HTT 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback